AKT1 and prostate cancer: This finding is consistent with the previous study showing that UA treatment inhibited phosphorylation of Akt and mTOR proteins in human LNCaP and PC-3 prostate cancer cells regardless of their status as androgen receptor or sensitivity to androgen [37].